Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia.
| Market Cap | 17.13 Million | Shares Outstanding | 7.448 Million | Avg 30-day Volume | 11.734 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.66 |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -8.656 Million |
| Price to Book Value | 0.366 | Operating Margin | 0.0 | Enterprise Value | 1.778 Million |
| Current Ratio | 12.01 | EPS Growth | 0.558 | Quick Ratio | 11.437 |
| 1 Yr BETA | 0.4472 | 52-week High/Low | 5.05 / 1.72 | Profit Margin | 0.0 |
| Operating Cash Flow Growth | -10.4258 | Free Cash Flow to Firm (FCFF) TTM | 13.616 Million | Free Cash Flow to Equity (FCFE) TTM | -9.673 Million |
| Altman Z-Score | -2.3482 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
0 | 2023-10-10 | 1 | |
|
37,895 | 2023-10-10 | 1 | |
|
494,698 | 2023-10-10 | 1 | |
|
1,312,420 | 2023-09-25 | 2 | |
|
1,173 | 2023-08-31 | 2 | |
|
MACDONALD R. LOCH CHIEF MEDICAL OFFICER |
|
0 | 2023-07-14 | 2 |
|
0 | 2023-07-14 | 1 | |
|
KOHLI PRASHANT CHIEF EXECUTIVE OFFICER |
|
0 | 2023-07-14 | 1 |
|
D'ANDREA CARRIE VP CLINICAL OPERATIONS |
|
0 | 2023-07-14 | 2 |
|
KUMAR AMRESH VP PROGRAM MANAGEMENT |
|
0 | 2023-07-14 | 2 |
|
45,000 | 2022-09-28 | 0 | |
|
LEMIEUX PIERRE COO, CANADA & CSO |
|
165,000 | 2022-06-22 | 0 |
|
D'ALVISE JANELLE PRESIDENT & CEO |
|
560,000 | 2022-06-22 | 0 |
|
FORD BRIAN D. CHIEF FINANCIAL OFFICER |
|
165,000 | 2022-06-22 | 0 |
|
42,100 | 2021-11-12 | 0 | |
|
42,100 | 2021-11-12 | 0 | |
|
4,689,547 | 2021-08-27 | 0 | |
|
GROCH BRIAN J. CHIEF COMMERCIAL OFFICER |
|
0 | 2020-04-01 | 0 |
|
BOILY JEAN-FRANCOIS VICE-PRESIDENT, FINANCE |
|
10,600 | 2020-04-01 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| ACASTI PHARMA INC ACST | 2023-12-08 22:15:04 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 21:45:04 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 21:15:04 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 20:45:04 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 20:15:07 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 19:45:04 UTC | -30.3528 | 35.6728 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 19:15:03 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 18:45:03 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 18:15:04 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 17:45:03 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 17:15:03 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 16:45:05 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 16:15:04 UTC | -30.0855 | 35.4055 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 15:45:04 UTC | -29.2838 | 34.6038 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 15:15:04 UTC | -29.2838 | 34.6038 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 14:45:04 UTC | -29.2838 | 34.6038 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 14:15:03 UTC | -29.2838 | 34.6038 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 13:45:03 UTC | -29.7601 | 35.0801 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 13:15:04 UTC | -29.7601 | 35.0801 | 150000 |
| ACASTI PHARMA INC ACST | 2023-12-08 12:45:05 UTC | -29.7601 | 35.0801 | 150000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
